Glitazone Use Associated with Diabetic Macular Edema

American Journal of Ophthalmology

Volumn 147, Issue 4, 2009, Pages

  Fong, Donald S ^a   Contreras, Richard ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DRUG SAFETY; EYE EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 62649174048     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.10.016     Document Type: Article

References (20)

1. Stumvoll M., and Hfaring H.U. Glitazones: clinical effects and molecular mechanisms. Ann Med 34 (2002) 217-224
2. Graham D.J., Green L., Senior J.R., and Nourjah P. Troglitzaone-induced liver failure: a case study. Am J Med 114 (2003) 299-306
3. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 123 (2005) 1273-1275
4. Ryan E.H., Han D.P., Ramsay R.C., et al. Diabetic macular edema associated with glitzone use. Retina 26 (2006) 562-570
5. Breslow N.E., and Day N.E. Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC Sci Publ (1987) 1-406
6. Shen L.Q., Child A., Weber G.M., et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 126 (2008) 793-799
7. Tokuyama T., Ikeda T., and Sato K. Effects of haemodialysis on diabetic macular leakage. Br J Ophthalmol 84 (2000) 1397-1400
8. Perkovich B.T., and Meyers S.M. Systemic factors affecting diabetic macular edema. Am J Ophthalmol 105 (1988) 211-212
9. Nesto R.W., Bell D., Bonow R.O., et al., American Heart Association, American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948
10. Avandia. [package insert]. http://us.gsk.com/products/assets/us_avandia.pdf Accessed: October 7, 2008
11. Raskin P., Rendell M., Riddle M.C., et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 (2001) 1226-1232
12. Niemeyer N.V., and Janney L.M. Thiazolidinedione-induced edema. Pharmacotherapy 22 (2002) 924-929
13. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
14. Bando Y., Ushiogi Y., Okafuji K., et al. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidae inhibitors. J Int Med Res 27 (1999) 53-64
15. Emoto M., Anno T., Sato Y., et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patient and its mRNA in 3T3-L1 adipocytes. Diabetes 50 (2001) 1166-1170
16. Wong T.Y., Klein R., Islam F.M., et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 141 (2006) 446-455
17. Do D.V., Shah S.M., Sung J.U., et al. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol 139 (2005) 620-623
18. Aroca P.R., Salvat M., Fernandez J., and Mendez I. Risk factors for diffuse and focal macular edema. J Diabetes Complications 18 (2004) 211-215
19. Asensio-Sanchez V.M., Gomez-Ramirez V., Morales-Gomez I., and Rodriguez-Vaca I. [Clinically significant diabetic macular edema: systemic risk factors]. Arch Soc Esp Oftalmol 83 (2008) 173-176
20. Girach A., and Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract 61 (2007) 88-97